
Ask a doctor about a prescription for OLMESARTAN/HYDROCHLOROTHIAZIDE VIATRIS 40 mg/25 mg FILM-COATED TABLETS
Package Leaflet: Information for the Patient
Olmesartan/Hydrochlorothiazide Viatris 40 mg/25 mg Film-Coated Tablets EFG
olmesartan medoxomil and hydrochlorothiazide
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
Olmesartan/Hydrochlorothiazide Viatris contains two active substances, olmesartan medoxomil and hydrochlorothiazide, which are used to treat high blood pressure (hypertension):
You will only be given olmesartan medoxomil/hydrochlorothiazide if treatment with olmesartan medoxomil alone has not controlled your blood pressure adequately. The combination of both active substances in this medicine has been shown to be more effective at lowering blood pressure than either substance alone.
You may already be taking medicines to treat high blood pressure, but your doctor may now want to treat you with olmesartan medoxomil/hydrochlorothiazide to lower it even more.
High blood pressure can be controlled with medicines such as olmesartan medoxomil/hydrochlorothiazide tablets. Your doctor may also have advised you to make changes to your lifestyle, such as losing weight, giving up smoking, reducing the amount of alcohol you drink, and reducing the amount of salt in your diet. Your doctor may also have advised you to take regular exercise, such as walking or swimming. It is important to follow your doctor's advice.
Do not take Olmesartan/Hydrochlorothiazide Viatris:
If you think any of these apply to you, or if you are not sure, do not take the tablets. Talk to your doctor and follow their advice.
Warnings and precautions
Consult your doctorbefore taking Olmesartan/Hydrochlorothiazide Viatris if you have any of the following health problems:
Your doctor may check your kidney function, blood pressure, and the levels of certain chemicals (e.g., potassium) in your blood at regular intervals.
Also, read the information in the "Do not take Olmesartan/Hydrochlorothiazide Viatris" section.
Your doctor may want to see you more often and do some tests if you have any of these conditions.
Olmesartan medoxomil/hydrochlorothiazide may cause an increase in the levels of fats and uric acid (which causes gout - painful swelling of the joints) in the blood. Your doctor will probably want to do a blood test from time to time to check for these possible changes.
A change in the levels of certain chemicals (electrolytes) in the blood may occur. Your doctor will probably want to do a blood test from time to time to check for this possible change. Some signs of electrolyte changes are: thirst, dry mouth, pain or muscle cramps, tired muscles, low blood pressure (hypotension), feeling of weakness, slowness, tiredness, sleepiness or restlessness, nausea, vomiting, decreased need to urinate, rapid heartbeat. Tell your doctor if you notice any of these symptoms.
As with any other medicine that lowers blood pressure, a severe drop in blood pressure in patients with heart or brain disease may cause a heart attack or stroke. Therefore, your doctor will closely monitor your blood pressure.
If you are going to have a parathyroid function test, you should stop taking olmesartan medoxomil/hydrochlorothiazide before the test.
Athletes are informed that this medicine may give a positive result in doping tests.
You must tell your doctor if you think you are (or might become) pregnant. Olmesartan medoxomil/hydrochlorothiazide is not recommended during pregnancy and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if taken after the third month of pregnancy (see section Pregnancy).
During treatment:
Contact your doctor if you experience any of the following side effects:
Children and adolescents (under 18 years)
Olmesartan medoxomil/hydrochlorothiazide is not recommended for children and adolescents under 18 years.
Black patients
As with other similar medicines, the blood pressure-lowering effect of olmesartan medoxomil/hydrochlorothiazide is somewhat smaller in black patients.
Other medicines and Olmesartan/Hydrochlorothiazide Viatris
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
In particular, tell your doctor or pharmacist about any of the following medicines:
Your doctor may need to change your dose and/or take other precautions:
If you are taking an ACE inhibitor or aliskiren (also read the information in the "Do not take Olmesartan/Hydrochlorothiazide Viatris" and "Warnings and precautions" sections).
Taking Olmesartan/Hydrochlorothiazide Viatris with alcohol
Be careful when drinking alcohol while taking olmesartan medoxomil/hydrochlorothiazide, as some people feel weak or dizzy. If this happens to you, do not drink any alcohol, including wine, beer, or drinks with alcohol.
Pregnancy and breastfeeding
Pregnancy
Tell your doctor if you think you are (or might become) pregnant or plan to become pregnant. Your doctor will normally advise you to stop taking olmesartan medoxomil/hydrochlorothiazide before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of olmesartan medoxomil/hydrochlorothiazide. Olmesartan medoxomil/hydrochlorothiazide is not recommended during pregnancy and must not be taken after the third month of pregnancy, as it may cause serious harm to your baby if taken after this time.
Breastfeeding
Tell your doctor if you are breastfeeding or about to start breastfeeding. Olmesartan medoxomil/hydrochlorothiazide is not recommended during breastfeeding. Your doctor may choose another treatment if you want to continue breastfeeding.
Ask your doctor or pharmacist for advice before taking any medicine.
Driving and using machines
You may feel drowsy or dizzy while being treated for high blood pressure. If this happens, do not drive or use machines until the symptoms have gone away. Ask your doctor.
Olmesartan/Hydrochlorothiazide Viatris contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per tablet; this is essentially "sodium-free".
Take this medicine exactly as your doctor or pharmacist has told you. If you are not sure, ask your doctor or pharmacist.
The recommended dose is one Olmesartan/Hydrochlorothiazide Viatris 40 mg/12.5 mg tablet per day. If your blood pressure is not controlled adequately, your doctor may change the dose to one Olmesartan/Hydrochlorothiazide Viatris 40 mg/25 mg tablet per day.
Swallow the tablet with water. If possible, take your dose at the same time each day, for example, at breakfast time.
If you take more Olmesartan/Hydrochlorothiazide Viatris than you should
If you take more tablets than you should or if a child accidentally takes one or more tablets, contact a doctor or go to the nearest hospital emergency department immediately and take the medicine pack with you. Signs of an overdose may include feeling unwell or sleepy, low blood pressure, causing weakness or dizziness, changes in heart rate or rhythm, or excessive thirst.
In case of overdose or accidental ingestion, contact your doctor or pharmacist or call the Toxicology Information Service, phone: 91 562 04 20, stating the medicine and the amount taken.
If you forget to take Olmesartan/Hydrochlorothiazide Viatris
If you forget to take a dose, take your normal dose the next day as usual. Do nottake a double dose to make up for forgotten doses.
If you stop taking Olmesartan/Hydrochlorothiazide Viatris
It is important to continue taking olmesartan medoxomil/hydrochlorothiazide unless your doctor tells you to stop.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
If you experience any of the following effects, stop takingolmesartanmedoxomil/hydrochlorothiazideand contact your doctor or go to the emergency center of the nearest hospital immediately:
Uncommon(may affect up to 1 in 100 people):
Rare(may affect up to 1 in 1,000 people):
Very Rare(may affect up to 1 in 10,000 people):
Frequency Not Known(cannot be estimated from the available data):
Olmesartan medoxomil/hydrochlorothiazide may cause a pronounced drop in blood pressure, in susceptible patients or as a result of an allergic reaction. Dizziness or weakness may occur infrequently. If this happens, stop taking olmesartanmedoxomil/hydrochlorothiazide, consult your doctor immediately, and remain lying down in a horizontal position.
Olmesartan medoxomil/hydrochlorothiazide is a combination of two active ingredients, and the following information, first, describes the adverse effects reported so far with the combination of olmesartan medoxomil and hydrochlorothiazide (in addition to those already mentioned), and second, the known adverse effects of the two active ingredients separately.
These are other known adverse effects reported so far with olmesartan medoxomil and hydrochlorothiazide taken simultaneously:
If these effects occur, they are often mild and it is not necessary to interrupt treatment.
Common(may affect up to 1 in 10 people):
Uncommon(may affect up to 1 in 100 people):
Also, some changes in blood test results have been observed infrequently, including:
Increased levels of fat in the blood, increased urea or uric acid in the blood, increased creatinine, increased or decreased potassium levels in the blood, increased calcium levels in the blood, increased blood sugar, increased liver function test values. Your doctor will monitor you with a blood test and tell you if you need to take any action.
Rare(may affect up to 1 in 1,000 people):
Also, some changes in blood test results have been observed in rare cases, including:
Increased blood urea nitrogen, decreased hemoglobin, and hematocrit values. Your doctor will monitor you with a blood test and tell you if you need to take any action.
Additional Adverse Effects Reported with the Use of Olmesartan Medoxomil or Hydrochlorothiazide Alone, but Not with OlmesartanMedoxomil/Hydrochlorothiazide:
Olmesartan Medoxomil:
Common(may affect up to 1 in 10 people):
Also, some changes in blood test results have been observed frequently, including:
Increased levels of substances that measure muscle function.
Uncommon(may affect up to 1 in 100 people):
Rare(may affect up to 1 in 1,000 people):
Very Rare(may affect up to 1 in 10,000 people):
Hydrochlorothiazide:
Common(may affect up to 1 in 10 people):
Also, some changes in blood test results have been observed, including:
Decreased levels of chloride, magnesium, or sodium in the blood, increased serum amylase (hyperamylasemia).
Uncommon(may affect up to 1 in 100 people):
Rare(may affect up to 1 in 1,000 people):
Very Rare(may affect up to 1 in 10,000 people):
Frequency Not Known(cannot be estimated from the available data):
Reporting of Adverse Effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that does not appear in this leaflet. You can also report them directly through the Spanish Medicines Surveillance System for Human Use: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not store above 25°C.
Do not use this medicine after the expiration date that appears on the carton and blister pack, after EXP. The expiration date is the last day of the month indicated.
Medicines should not be disposed of via wastewater or household waste. Deposit the containers and medicines you no longer need at the SIGRE collection point in the pharmacy. In case of doubt, ask your pharmacist how to dispose of the containers and medicines you no longer need. This way, you will help protect the environment.
Composition of Olmesartan/Hydrochlorothiazide Viatris
The active ingredients are:
Each tablet contains 40 mg of olmesartan medoxomil and 25 mg of hydrochlorothiazide
The other ingredients are:
(core of the tablet) sodium croscarmellose (E466), mannitol (E421), microcrystalline cellulose (E460i), low-substituted hydroxypropylcellulose (E463), anhydrous colloidal silica (E551), magnesium stearate (E572), sodium lauryl sulfate (E487), and
(tablet coating) hypromellose (E464), titanium dioxide (E171), macrogol, talc (E553b). See section 2 "Olmesartan/Hydrochlorothiazide Viatris contains sodium".
Appearance of the Product and Package Contents
Olmesartan/Hydrochlorothiazide Viatris are film-coated tablets, white, oblong, biconvex, with beveled edges, marked with "M" on one face and "H7" on the other.
Available in blister packs of 14, 28, 30, 56, 90, and 98 tablets, and calendar packs of 28 tablets.
Not all pack sizes may be marketed.
Marketing Authorization Holder
Viatris Limited
Damastown Industrial Park
Mulhuddart, Dublin 15
Dublin
Ireland
Manufacturer
Mylan Hungary Kft.
H-2900, Komárom
Mylan utca 1
Hungary
You can request more information about this medicine by contacting the local representative of the marketing authorization holder:
Viatris Pharmaceuticals, S.L.
C/ General Aranaz, 86
28027 - Madrid
Spain
This medicine is authorized in the Member States of the European Economic Area with the following names:
Spain | Olmesartán/Hidroclorotiazida Viatris 40 mg/12.5 mg, 40 mg/25mg film-coated tablets EFG |
Greece | Olmesartan/HCTZ Mylan 40 mg/12.5 mg, 40 mg/25 mg film-coated tablets |
Ireland | Olmesartan medoxomil/Hydrochlorothiazide 20 mg/12.5 mg, 20 mg/25 mg film-coated tablets |
Portugal | Olmesartan + Hydrochlorothiazide Mylan |
Date of the Last Revision of this Leaflet: September 2024
Detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (https://www.aemps.gob.es/)
The average price of OLMESARTAN/HYDROCHLOROTHIAZIDE VIATRIS 40 mg/25 mg FILM-COATED TABLETS in December, 2025 is around 20.18 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for OLMESARTAN/HYDROCHLOROTHIAZIDE VIATRIS 40 mg/25 mg FILM-COATED TABLETS – subject to medical assessment and local rules.